FinanceAsia: Deals Ramp Up in Asia’s Healthcare Space with Cancer Focus
May 28, 2024
O’Melveny represented Sunho Biologics, Inc. on its initial public offering and listing on the Main Board of the Hong Kong Stock Exchange. The offering size was approximately HK$460 million (approximately US$60 million). O’Melveny advised Sunho Biologics on both Hong Kong and US law. This is the second listing of a Chapter 18A biotech company in 2024, and O’Melveny has advised on both transactions. The O’Melveny team was led by partners Ke Geng and Ke Zhu.
Read the full article here.